» Articles » PMID: 28390158

Lithium Chloride Inhibits Early Stages of Foot-and-mouth Disease Virus (FMDV) Replication in Vitro

Overview
Journal J Med Virol
Specialty Microbiology
Date 2017 Apr 9
PMID 28390158
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Foot-and-mouth disease virus (FMDV) causes an economically important and highly contagious disease of cloven-hoofed animals such as cattle, swine, and sheep. FMD vaccine is the traditional way to protect against the disease, which can greatly reduce its occurrence. However, the use of FMD vaccines to protect early infection is limited. Therefore, the alternative strategy of applying antiviral agents is required to control the spread of FMDV in outbreak situations. As previously reported, LiCl has obviously inhibition effects on a variety of viruses such as transmissible gastroenteritis virus (TGEV), infectious bronchitis coronavirus (IBV), and pseudorabies herpesvirus and EV-A71 virus. In this study, our findings were the first to demonstrate that LiCl inhibition of the FMDV replication. In this study, BHK-21 cell was dose-dependent with LiCl at various stages of FMDV. Virus titration assay was calculated by the 50% tissue culture infected dose (TCID ) with the Reed and Muench method. The cytotoxicity assay of LiCl was performed by the CCK8 kit. The expression level of viral mRNA was measured by RT-qPCR. The results revealed LiCl can inhibit FMDV replication, but it cannot affect FMDV attachment stage and entry stage in the course of FMDV life cycle. Further studies confirmed that the LiCl affect the replication stage of FMDV, especially the early stages of FMDV replication. So LiCl has potential as an effective anti-FMDV drug. Therefore, LiCl may be an effective drug for the control of FMDV. Based on that, the mechanism of the antiviral effect of LiCl on FMDV infection is need to in-depth research in vivo.

Citing Articles

Reimagining safe lithium applications in the living environment and its impacts on human, animal, and plant system.

Shakoor N, Adeel M, Ahmad M, Zain M, Waheed U, Javaid R Environ Sci Ecotechnol. 2023; 15:100252.

PMID: 36891261 PMC: 9988428. DOI: 10.1016/j.ese.2023.100252.


Impact of SARS-CoV-2 on Host Factors Involved in Mental Disorders.

Rhoades R, Solomon S, Johnson C, Teng S Front Microbiol. 2022; 13:845559.

PMID: 35444632 PMC: 9014212. DOI: 10.3389/fmicb.2022.845559.


Lithium salts as a treatment for COVID-19: Pre-clinical outcomes.

Soriano-Torres O, Noa Romero E, Gonzalez Sosa N, Enriquez Puertas J, Fragas Quintero A, Garcia Montero M Biomed Pharmacother. 2022; 149:112872.

PMID: 35364381 PMC: 8947939. DOI: 10.1016/j.biopha.2022.112872.


Potential mechanisms underlying lithium treatment for Alzheimer's disease and COVID-19.

Wei H, Anchipolovsky S, Vera R, Liang G, Chuang D Eur Rev Med Pharmacol Sci. 2022; 26(6):2201-2214.

PMID: 35363371 PMC: 9173589. DOI: 10.26355/eurrev_202203_28369.


Lithium chloride inhibits infectious bronchitis virus-induced apoptosis and inflammation.

Liu X, Chang X, Wu Q, Xu J, Chen L, Shen R Microb Pathog. 2021; 162:105352.

PMID: 34883226 PMC: 8648602. DOI: 10.1016/j.micpath.2021.105352.


References
1.
Knowles N, Samuel A . Molecular epidemiology of foot-and-mouth disease virus. Virus Res. 2003; 91(1):65-80. DOI: 10.1016/s0168-1702(02)00260-5. View

2.
Domingo E, Escarmis C, Baranowski E, Ruiz-Jarabo C, Carrillo E, Nunez J . Evolution of foot-and-mouth disease virus. Virus Res. 2003; 91(1):47-63. DOI: 10.1016/s0168-1702(02)00259-9. View

3.
Cernescu C, Popescu L, Constantinescu S, Cernescu S . Antiviral effect of lithium chloride. Virologie. 1988; 39(2):93-101. View

4.
Hung H, Shih S, Chang T, Fang M, Hsu J . The combination effects of licl and the active leflunomide metabolite, A771726, on viral-induced interleukin 6 production and EV-A71 replication. PLoS One. 2014; 9(11):e111331. PMC: 4239034. DOI: 10.1371/journal.pone.0111331. View

5.
Golde W, Pacheco J, Duque H, Doel T, Penfold B, Ferman G . Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: Use in emergency outbreak response. Vaccine. 2005; 23(50):5775-82. DOI: 10.1016/j.vaccine.2005.07.043. View